Revenue: As of FY2025, the actual value is USD 427 M.

Financial Metrics Summary

Revenue and Operational Metrics

• GeneDx Holdings Corp. reported full year 2025 revenues of $427 million, with exome and genome revenue increasing by 54% (58% excluding a one-time 2024 benefit). Fourth quarter 2025 revenues were $121 million, with a 32% increase in exome and genome revenue (43% excluding a one-time 2024 benefit).
• Exome and genome test result volume for the full year 2025 was 97,271, marking a 30.5% year-over-year increase. The fourth quarter saw a volume of 27,761, a 34.3% increase year-over-year.
• The adjusted gross margin for both the full year and fourth quarter of 2025 was 71%.

Cash Flow

• As of December 31, 2025, GeneDx Holdings Corp. had cash, cash equivalents, marketable securities, and restricted cash totaling approximately $172 million.

Unique Metrics

• The company experienced a significant increase in exome and genome test result volumes, with a 30.5% increase for the full year 2025 and a 34.3% increase in the fourth quarter.

Outlook / Guidance

• For the full year 2026, GeneDx Holdings Corp. expects revenues to be between $540 and $555 million, with exome and genome revenue and volume growth anticipated to be between 33% to 35%. The adjusted gross margin is expected to be at least 70%, and the adjusted net income is projected to remain positive.